title: Lenalidomide, melphalan and dexamethasone in a population of patients with immunoglobulin light chain amyloidosis with high rates of advanced cardiac involvement.
abstract: Immunoglobulin light chain amyloidosis remains incurable despite recent therapeutic advances, and is particularly difficult to treat in patients with amyloid cardiomyopathy. Based on evidence of activity in multiple myeloma, we designed a pilot study of an oral regimen of lenalidomide in combination with dexamethasone and low-dose melphalan in order to evaluate its safety and efficacy in patients with amyloidosis, including those with advanced cardiac involvement. Twenty-five patients were enrolled. Ninety-two percent of patients had cardiac involvement by amyloidosis, and 36% of patients met the criteria for Mayo Clinic cardiac stage III disease. Patients received up to nine cycles of treatment, consisting of lenalidomide 10 mg/day orally on days 1 - 21 (28-day cycle); melphalan 0.18 mg/kg orally on days 1-4; and dexamethasone 40 mg orally on days 1, 8, 15, and 22. High rates (33%) of cardiac arrhythmias and low rates of treatment completion (12.5%) were observed. Ten patients died during the study, all within the first several months of treatment due to acute cardiac events. The overall hematologic response rate was 58%, however organ responses were seen in only 8% of patients. The overall survival rate at 1 year was 58%. While we confirmed the hematologic response rates observed with similar regimens, front-line treatment with melphalan, lenalidomide and dexamethasone was toxic, ineffective, and did not alter survival outcomes for patients with high-risk cardiac disease. Our data highlight the importance of developing novel treatment approaches for amyloid cardiomyopathy. This trial was registered at www.clinicaltrials.gov (NCT00890552).
authors.affiliation: mliedtke@stanford.edu.
authors.forename: Shira
authors.initials: S
authors.lastname: Dinner
authors.forename: Wesley
authors.initials: W
authors.lastname: Witteles
authors.forename: Anosheh
authors.initials: A
authors.lastname: Afghahi
authors.forename: Ronald
authors.initials: R
authors.lastname: Witteles
authors.forename: Sally
authors.initials: S
authors.lastname: Arai
authors.forename: Richard
authors.initials: R
authors.lastname: Lafayette
authors.forename: Stanley L
authors.initials: SL
authors.lastname: Schrier
authors.forename: Michaela
authors.initials: M
authors.lastname: Liedtke
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000686:Amyloidosis / Q000188:drug therapy* / Q000453:epidemiology / Q000401:mortality; D015331:Cohort Studies; D003907:Dexamethasone / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D005260:Female; D006331:Heart Diseases / Q000188:drug therapy* / Q000453:epidemiology / Q000401:mortality; D006801:Humans; D007147:Immunoglobulin Light Chains; D000077269:Lenalidomide; D008297:Male; D008558:Melphalan / Q000008:administration & dosage*; D008875:Middle Aged; D010865:Pilot Projects; D015996:Survival Rate / Q000639:trends; D013792:Thalidomide / Q000008:administration & dosage / Q000031:analogs & derivatives*
chemical_list: D007147:Immunoglobulin Light Chains; D013792:Thalidomide; D003907:Dexamethasone; D000077269:Lenalidomide; D008558:Melphalan